An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds)

Trial Profile

An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
  • Indications Anal cancer; Cervical cancer; Condylomata acuminata; Human papillomavirus infections; Vulvovaginal cancer
  • Focus Pharmacodynamics; Registrational
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 14 Feb 2018 Planned End Date changed from 2 Nov 2018 to 23 Nov 2018.
    • 14 Feb 2018 Planned primary completion date changed from 2 Nov 2018 to 23 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top